Abstract

Whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or sodium-glucose co-transporter 2 inhibitors (SGLT2is) are cost-effective when considering solely their cardiorenal benefits is unknown. We projected the incidence and costs of hospitalisation for myocardial infarction (MI), stroke, and heart failure (HF), and end-stage kidney disease (ESKD) among people with type 2 diabetes under scenarios of widespread use of these drugs, from an Australian healthcare perspective.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call